Clinical Trials for Refractory Multiple Myeloma

Find clinical trials for refractory multiple myeloma. Discover research opportunities and treatment options in your area.

29 Active Trials Found

Showing 29 trials on this page

Page 1 of 2

A Study to Evaluate Preventive Treatments for Talquetamab-related Oral Toxicity

NCT ID: NCT06500884

This clinical trial is looking at ways to prevent a side effect called distorted taste (or dysgeusia) that some patients experience while taking a medication called talquetamab for multiple myeloma...

Recruiting

Phase: PHASE2 Type: interventional Locations: Durham, North Carolina, United States, Rochester, New York, United States +25 more

Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma

NCT ID: NCT06421675

This clinical trial is studying a new treatment called elranatamab for patients with relapsed or refractory multiple myeloma, which means that their cancer has come back or hasn’t responded to prev...

Recruiting

Phase: PHASE2 Type: interventional Locations: Edmonton, Alberta, Canada, Ottawa, Ontario, Canada +4 more

Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma

NCT ID: NCT05847569

This clinical trial is studying a treatment called belantamab mafodotin for patients with a type of blood cancer known as multiple myeloma that has either come back after treatment or has not respo...

Recruiting

Phase: PHASE2 Type: interventional Locations: Jacksonville, Florida, United States

Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease

NCT ID: NCT06627751

This clinical trial is studying a combination of three medications—mezigdomide, carfilzomib, and dexamethasone—to see how effective they are in treating multiple myeloma that has either returned af...

Recruiting

Phase: PHASE2 Type: interventional Locations: Buffalo, New York, United States

Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse

NCT ID: NCT06948084

This clinical trial is studying a new combination of medications, daratumumab and teclistamab, to see if it works better than the usual treatments for patients with multiple myeloma that has either...

Not yet recruiting

Phase: PHASE2 Type: interventional

Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

NCT ID: NCT06940297

This clinical trial is studying a new treatment approach for patients with multiple myeloma, a type of blood cancer that has either returned after treatment or hasn’t responded to previous therapie...

Not yet recruiting

Phase: PHASE2 Type: interventional Locations: Rochester, Minnesota, United States

A Study to Learn How Patients With Triple Class Refractory Multiple Myeloma (TCR-MM) Are Treated in Italian Centers for Blood Related Diseases

NCT ID: NCT05742217

This clinical trial is studying how patients with a specific type of multiple myeloma, called Triple Class Refractory Multiple Myeloma (TCR-MM), are treated in various blood disease centers in Ital...

Recruiting

Type: observational Locations: Meldola (Fc), , Italy

Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma

NCT ID: NCT06465316

This clinical trial is studying a new treatment approach for patients with relapsed or refractory multiple myeloma, a type of blood cancer that keeps coming back or does not respond to existing tre...

Recruiting

Phase: PHASE1 Type: interventional Locations: New Haven, Connecticut, United States, Oklahoma City, Oklahoma, United States +5 more

²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma

NCT ID: NCT04579523

This clinical trial is studying a new treatment approach for patients with high-risk multiple myeloma, which is a type of blood cancer. The treatment involves a special drug called ²¹¹At-OKT10-B10,...

Not yet recruiting

Phase: PHASE1 Type: interventional Locations: Seattle, Washington, United States

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

NCT ID: NCT06119685

This clinical trial is studying a new treatment called IDP-023 for patients with advanced blood cancers, such as multiple myeloma and non-Hodgkin lymphoma. Researchers want to find out how safe thi...

Recruiting

Phase: PHASE1 Type: interventional Locations: Minneapolis, Minnesota, United States, Providence, Rhode Island, United States +12 more

TriPRIL CAR T Cells in Multiple Myeloma

NCT ID: NCT05020444

This clinical trial is studying a new treatment called TriPRIL CAR T Cells for patients with multiple myeloma, which is a type of blood cancer that can return after treatment or become resistant to...

Recruiting

Phase: PHASE1 Type: interventional Locations: Boston, Massachusetts, United States

Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma

NCT ID: NCT06433947

This clinical trial is studying a new treatment called OPN-6602 for patients with relapsed multiple myeloma, which means their cancer has come back after treatment, or refractory multiple myeloma, ...

Recruiting

Phase: PHASE1 Type: interventional Locations: Rochester, New York, United States, Boston, Massachusetts, United States +8 more

Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

NCT ID: NCT06348108

This clinical trial is studying a new treatment combination for patients with multiple myeloma, a type of blood cancer that can come back after treatment or does not respond to previous therapies. ...

Not yet recruiting

Phase: PHASE1 Type: interventional Locations: San Francisco, California, United States

SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

NCT ID: NCT06622005

This clinical trial is studying a new treatment approach for patients with multiple myeloma, a type of blood cancer that has either come back after treatment or has not responded to earlier therapi...

Recruiting

Phase: PHASE1 Type: interventional Locations: Buffalo, New York, United States

Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma

NCT ID: NCT06232044

This clinical trial is investigating the safety and effectiveness of a new combination treatment for patients with multiple myeloma, a type of blood cancer that affects the immune system. The treat...

Not yet recruiting

Phase: PHASE1 Type: interventional Locations: Milwaukee, Wisconsin, United States, New York, New York, United States +33 more

Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma

NCT ID: NCT06203912

This clinical trial is studying a new treatment for patients with multiple myeloma, a type of blood cancer that has either returned after treatment (relapsed) or has not responded to previous thera...

Recruiting

Phase: PHASE1 Type: interventional Locations: Columbus, Ohio, United States

Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies

NCT ID: NCT05981209

This clinical trial is studying a new combination of treatments for patients with multiple myeloma, a type of blood cancer that has returned after previous therapies or does not respond to them. Th...

Recruiting

Phase: PHASE1 Type: interventional Locations: Columbus, Ohio, United States

Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma

NCT ID: NCT05896228

This clinical trial is exploring a new treatment combination for patients with relapsed or refractory multiple myeloma, a type of cancer that affects plasma cells in the blood. The treatment being ...

Recruiting

Phase: PHASE2 Type: interventional Locations: Miami, Florida, United States

MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM

NCT ID: NCT06171685

The MMRC Horizon One Adaptive Platform Trial is studying new treatments for patients with relapsed or refractory multiple myeloma, which is a type of blood cancer that has come back or is not respo...

Recruiting

Phase: PHASE2 Type: interventional Locations: Rochester, Minnesota, United States, Boston, Massachusetts, United States +12 more

A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma

NCT ID: NCT06799026

This clinical trial is exploring a new treatment approach for patients with relapsed or refractory multiple myeloma, which is a type of blood cancer. The study will assess the safety and effectiven...

Not yet recruiting

Phase: PHASE1 Type: interventional Locations: Boston, Massachusetts, United States, Boston, Massachusetts, United States

Related Conditions

Breast Cancer View clinical trials → Stroke View clinical trials → Obesity View clinical trials → Cancer View clinical trials → Healthy View clinical trials → Prostate Cancer View clinical trials →

Search All Trials Browse All Conditions